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Introduction 
Pediatric obesity and overweight is an undisputed health crisis.  Labeled an epidemic in 
1998 by the World Health Organization, it is imperative to intervene early, identifying at-risk 
patients and implementing treatment plans for those already overweight (Edmunds, Waters, & 
Elliot, 2001).  Obese and overweight patients can present a difficult task for the primary care 
provider.  There is an obligation to educate and promote preventive behaviors, but the audience 
can be unreceptive.  As the nation’s adult population has increased in weight, a similar change 
is occurring in the nation’s youth (Inge et al., 2004).  Insidious lifestyle changes that have 
plagued the adult population, such as decreased physical activity and increased consumption of 
calorie-dense, nutrient-deficient foods, have had similar effects on the pediatric population.  In 
a promising light, it has been shown that overweight pediatric patients are more successful with 
weight loss and maintenance than their adult counterparts (Epstein, Myers, Raynor, & Saelens, 
1998; Kitzman & Beech, 2006). 
Pediatric weight trends have been tracked since the 1960’s by the National Health and 
Nutrition Examination Survey (NHANES).  NHANES I (1963-1970), II (1976-1980), III   
(1988-1994), and IV (1999-2000) have been completed, showing a relatively stable prevalence 
of overweight among children from 1963-1980, ranging between 4%-6.5%.  By 1988, the 
prevalence was 11.5%, and as of 2004, an estimated 17% of youth age 2-19 were overweight 
(Ogden et al., 2006). 
Recent recommendations of the International Task Force on Obesity use the criteria of 
> 95
th percentile of weight for age and gender to define pediatric overweight, using obese and 
overweight as interchangeable terms in the pediatric population.  Since BMI is not a linear 
progression in childhood and is an imprecise measure of adiposity in children, percentiles, and   2
not absolute values, are used to track children’s weight changes (Kirk, Scott, & Daniels, 2005).  
Former guidelines stated that children > 85
th percentile were considered overweight and >95
th 
percentile considered obese.  Currently, due to the difficulty in unanimous labeling, weights 
between the 85
th and 95
th percentile are considered “at risk for overweight” (Barlow & Dietz, 
1998; Whitlock, Williams, Gold, Smith, & Shipman, 2005). 
In spite of the wide variety of interventions available to treat obesity, it has been shown 
that prevention is the best way to avoid obesity, both in children and adults (Whitlock et al., 
2005).  Noller and Paulk (2005) reported that with long term follow-up, 80-90% of overweight 
children who have achieved weight loss will return to pre-intervention weights; yet, Epstein has 
reported 33% of one study cohort remaining at non-obese BMI percentiles in 10 years of 
follow-up (Epstein et al., 1998).  Researchers also found that 25% to 41% of obese preschool-
age children are likely to be obese as adults and 42% to 63% of obese school-age children will 
remain so into adulthood (Noller & Paulk).  However, other studies have reported that 
overweight children less than 12 years old, including those above the 95
th percentile, will not 
necessarily become obese adults (Whitlock et al.). 
The recent surge in obesity in both adults and children has prompted studies examining 
the cause of the excess weight.  The federal nutritional guidelines, published in the 1970’s, set 
the recommendations for dietary intake of carbohydrates (50%), protein (20%), and fat (30%) 
(Slyper, 2004).  In studies done by Wright et al adolescent intake of fat was very close to the 
recommended intake, leading investigators to suspect increased refined carbohydrate intake to 
be a substantial contributor to the obesity epidemic (Bialostosky, Wright, Kennedy-Stephenson, 
McDowell, & Johnson, 2002; Plourde, 2006; Wright, Wang, Kennedy-Stephenson, & Ervin, 
2003).  Also, studies have found that calorie intake among children has been roughly the same   3
since the 1970’s , supporting the theory that a decrease in energy expenditure is a causative 
factor in the obesity epidemic (Noller & Paulk, 2005; Slyper).  The combination of 
technologies that are very enticing for children (television, video games, computer) and a lack 
of safe outdoor areas to play maybe contributing to the decrease in energy expenditure (Noller 
& Paulk).  The increases in BMI have been more pronounced in the upper ranges of BMI, 
meaning that those who were already overweight are increasing their BMIs more than those 
with a normal BMI (Whitlock et al., 2005).  This phenomenon has led to the widely supported 
theory of “obesity susceptibility genes” that are being acted on and activated by environmental 
factors.  It is suspected that approximately 50% of the population has these genes (Whitlock et 
al.). 
 
 
Review Methodology 
Studies have been identified from MEDLINE, PubMed, and CINAHL.  Keywords and search 
terms include obesity, pediatric obesity, behavior modification, bariatric surgery, gastric 
bypass, non-prescription antiobesity agents, weight loss and motivation, antiobesity agents and 
weight loss motivation, and obesity interventions.  The abstract or article will be assessed for 
compliance with the BMI percentile categories.  Inclusion criteria includes: classifying children 
according to the CDC’s age- and gender-specific BMI percentiles, and age between 2 to 19 
years.  Exclusion criteria include classifying by triceps skinfold thickness or percent over ideal 
body weight without inclusion of a BMI measurement, and age < 2 years or > 19 years.   4
Comorbidities of Pediatric Overweight 
Recent research has reported findings of obesity-related morbidities appearing in 
children that were previously seen only in adult populations, including cardiovascular 
conditions, sleep apnea, and orthopedic problems.  The relationship between pediatric 
overweight and cardiovascular dysfunction is well-represented in the literature and includes 
hypertension, dyslipidemia, and insulin resistance and type II diabetes (Whitlock et al., 2005).  
The major concern regarding hypertension is its association with cardiovascular and renal 
disease (Mitsnefes, 2006).  While still low, prevalence rates of pediatric hypertension have 
been increasing over the past decade, and it is recognized as an important health care issue. 
Essential hypertension is now the most common type of hypertension in children older than 10 
years (Mitsnefes).  Childhood hypertension is strongly correlated with adult hypertension and 
cardiovascular disease.  Common cholesterol findings in obese children include elevated low-
density lipoprotein (LDL) cholesterol, decreased high-density lipoprotein cholesterol (HDL), 
and elevated triglycerides.  Central fat disposition is thought be an important causative factor in 
pediatric hyperlipidemia (Dietz, 1998).  Diagnosis of type II diabetes in childhood raises 
concerns regarding earlier onset of advanced complications, including cardiovascular disease, 
renal failure and amputations (Must & Anderson, 2003).  Basal insulin secretion, stimulated 
insulin secretion and insulin resistance are directly related to the amount of visceral fat present; 
however it is unclear whether visceral or total body fat plays a larger role in insulin and glucose 
metabolism (Dietz).  There is also an increased risk of hepatic steatosis in overweight children, 
leading to liver dysfunction and elevated transaminase levels (Noller & Paulk, 2005). 
Sleep apnea occurs in an estimate 7% of obese children and is an indication for 
aggressive obesity treatment (Dietz, 1998).  A study by Silvesti et al found that children >200%   5
above ideal body weight had oxygen saturation below 90% for more than half the total sleep 
time (Must & Strauss, 1999).  Also of concern are the neurocognitive defects and daytime 
sleepiness noted in children with obesity related sleep apnea (A. Must & Strauss, 1999).  
Obesity hypoventilation syndrome is a newer phenomenon, whose relationship with sleep 
apnea is unclear, but is also associated with high mortality and thus should be aggressively 
treated (Dietz, 1998).  The long term health consequences of these morbidities are profound 
and cumulative.  Early intervention is necessary to prevent severe future health problems and 
disability. 
Also of concern in obese children is slipped capital femoral epiphysis (SCFE), which is 
one of the indications for immediate weight loss intervention.  SCFE occurs when repetitive 
strain causes the femoral head to slip off the femoral neck at the epiphysis.  This causes 
necrosis of the femoral head in 30% of affected children and is a surgical emergency (Noller & 
Paulk, 2005). 
The rise in pediatric obesity has correlated with a rise in conditions known to cause dire 
long-term health consequences.  Children and adolescents are more frequently being diagnosed 
with type II diabetes, sleep apnea and hypertension, conditions previously relegated to the adult 
population (Must & Anderson, 2003).  To prevent future complications, it is imperative to 
address weight control early and promptly implement a weight loss plan.   6
Psychological Impact of Pediatric Overweight 
Data collected on the psychological impact of obesity has shown obese children to also 
suffer from low self-esteem, depression, and anxiety.  Social isolation, stigmatization and 
discrimination are also challenges facing the overweight child (Warschburger, 2005).  Obesity 
onset in childhood is a major factor in the social effect of overweight, especially in middle 
childhood.  Overweight at this stage of development leads to poor self-image and low self-
esteem.  Furthermore, the negative self-image and concern over body image are more likely to 
persist through adulthood, as compared to those who became obese in adulthood and suffer 
only minor disturbances in body image (Must & Strauss, 1999). 
Although the prevalence of obesity has increased greatly and it is believed to be a 
tolerated condition, bias against obese children is actually greater now than 40 years ago 
(Warschburger, 2005).  Overweight children are teased by peers three times as much as normal 
weight children, but weight-related comments were also reported from children of other ages, 
family members and even strangers (Warschburger).  Rates of depression among overweight 
youth have been estimated as high as 43% and anxiety, especially social anxiety, is four times 
higher in obese youth than children with other chronic diseases (Warschburger).  It has been 
shown that children who mature earlier (younger than 11 years old for girls and younger than 
12 years old for boys) tend to have lower self-esteem than their peers; however this 
phenomenon has not been separated from concurrent overweight and early maturation (Dietz, 
1998).  Overweight children with low self-esteem are also more likely to smoke or use alcohol 
(Whitlock et al., 2005). 
Another study points out that psychological data are most often gathered in the 
populations of children presenting to a clinician for weight management help and are therefore   7
more likely to feel despair about their condition (Flodmark, 2005).  In community samples 
studied, quality of life as rated by children, both overweight and normal weight, using the Self-
perception Profile for children showed few significant differences.  Overweight children rated 
athletic abilities and physical appearance as less important than normal weight peers, but 
showed no deficits in social or academic functioning (Flodmark).  Flodmark also suggests that 
any functional deficits apparent in obese children might be ameliorated by increased social and 
familial support.  Dietz reports that overweight children do not have low self-esteem, but a 
negative self-image develops in adolescence and is likely to persist into adulthood (Dietz, 
1998).  Children as young as six have been shown to be prejudiced against overweight children, 
rating them as undesirable friends, cheaters, lazy, and ugly (Dietz).  The social stigma extends 
past childhood, as overweight adult women have been shown to complete fewer years of 
school, have a lower income and were less likely to marry (Dietz; Must & Strauss, 1999; Noller 
& Paulk, 2005).  Other studies found overweight applicants to be less likely to be accepted to 
an elite college as other, normal weight applicants with similar qualifications (Dietz; Must & 
Strauss).  These findings were not apparent among overweight young men. 
Reports vary regarding whether overweight children suffer psychologically from the 
condition.  It is reasonable to assume that strong familial or peer support can lessen any social 
or functional deficits perceived by the overweight child.  However, a strong societal bias 
against the overweight may counteract personal support.  As a clinician, the best option would 
be to advise family to provide strong support for the child in any measures that might improve 
self-esteem and especially health behaviors.   8
Assessment 
It is vitally important for the primary care provider to routinely assess pediatric patients 
for weight gain.  If a child is >95
th percentile for height or >85
th percentile with comorbidities, 
such as hypertension, musculoskeletal complaints, or hyperinsulinemia, an in-depth medical 
assessment should be performed (Barlow & Dietz, 1998).  The assessment includes ruling out 
any exogenous causes of obesity, including genetic syndromes, endocrine syndromes, or 
psychological disorders.  Secondly, any complications of obesity must be recognized and the 
effects treated or minimized.  Common comorbidities are discussed below.  Laboratory tests 
that ought to be performed include a lipoprotein profile, liver function tests (AST, ALT), 
glucose tolerance test and hemoglobin A1C if appropriate.  A thorough history and physical 
exam should also be performed, looking specifically for any of the symptoms or physical 
findings associated with obesity related comorbidities: hip or knee pain or limited range of 
motion at hip, acanthosis nigricans, blurred optic disks, and tibia vara (Barlow & Dietz; Noller 
& Paulk, 2005).  The clinician must also assess the parent and child’s acceptance of the 
condition and willingness to change behaviors and tailor education messages and suggestions to 
their motivation level (Young, 2005).  Obesity must be treated as a chronic condition, with 
regular follow-up as appropriate.  Also, due to the stigma associated with being obese, the 
clinician must approach the patient in a sensitive, non-judgmental, and caring manner (Barlow 
& Dietz).  If the patient senses negativity or disgust from the clinician, therapy is much more 
likely to be unsuccessful (Barlow & Dietz).   9
Clinician Attitudes Toward Treatment of Pediatric Obesity 
The primary care provider is obligated to address the issue of overweight with the child 
and parent.  In a survey of New England area pediatricians (n = 1243), participants agreed the 
role of the clinician is to educate the patient and parent about the health consequences of excess 
weight, give advice and support on diet and exercise, and refer to a dietitian (Jelalian, Boergers, 
Alday, & Frank, 2003).  However, the rates at which pediatric providers do so varies.  With 
mildly overweight children (10%-19% over ideal body weight (IBW)), who may be in the 
easiest position to lose weight, providers discuss weight issues only 25% of the time.  This 
percentage increases to roughly 60% for mildly obese patients (20%-30% over IBW), and more 
than 90% of visits with severely overweight patients (100% or more over IBW) (Jelalian et al.).  
This dearth of discussion concerning a major public health issue is due to three factors: lack of 
confidence in competency, lack of support staff, and lack of reimbursement.  Three-quarters of 
the New England pediatricians surveyed labeled themselves as incompetent in terms of treating 
pediatric obesity.  This perceived incompetence led to discomfort in addressing and treating 
pediatric overweight, and fewer recommended therapies (Jelalian et al.).  Brief but consistent 
counseling has been shown effective with promoting adults to lose weight, and though similar 
studies have not been done in children, it is not unreasonable to assume the same would be true 
(Gilbert & Fleming, 2006).  Also, pediatricians cited smoking, alcohol consumption, and sexual 
activity as more immediate concerns and thus education about these issues precede education 
about weight issues (Jelalian et al.).  Given the limited amount of time allotted for a patient 
visit and the difficulty inherent in losing weight, it would benefit the patient and provider to be 
able to begin treatment with the most efficacious plan for long term adherence and benefit.   10
Intervention for Pediatric Overweight 
The remainder of this literature review will include research on interventions for 
pediatric overweight from 1995 to the present.  Four frequently implemented treatment plans 
for pediatric overweight will be discussed, 1) behavior modification, 2) prescription 
intervention, 3) over-the-counter medication intervention, and 4) bariatric surgery. 
Therapies to be discussed in this paper include behavior modification, prescription 
therapy, over-the-counter interventions, and surgical interventions.  Selecting a management 
plan for pediatric overweight must include consideration of maintaining the normal growth and 
development of the child (Kirk et al., 2005).  In fact, for uncomplicated overweight, weight 
maintenance is the recommended first-line therapy.  The goal is to maintain the child’s current 
weight, allowing for a reduction in BMI as the child grows taller (Barlow & Dietz, 1998; 
Ritchie, Crawford, Hoelscher, & Sothern, 2006).  This strategy requires only modest alterations 
in diet and activity, making it a realistic option (Barlow & Dietz). 
 
Behavior Modification 
The most extensively studied intervention in pediatric populations is behavior 
modification.  Behavior modification is a series of comprehensive lifestyle changes with the 
goal of attainment of a healthy weight for the child.  The targets of behavior modification 
include improved diet, increased physical activity with a decrease in sedentary behaviors, 
stimulus and impulse control, pre-planning, goal setting, self-monitoring, and reward. In 
implementing treatment, individual or multiple components can be targeted, depending on the 
motivation or expected adherence of the patient, realizing that modifying one behavior will be 
easier than modifying many.   11
Behavior modification can be implemented in a variety of settings; however a family-
based therapy is generally more effective in younger children aged 5 to 12 years.  School-based 
therapy can be effective in adolescents (Ritchie et al., 2006).  It has been suggested that early 
adolescence coincides with a shift of locus of control over health issues for children, which 
means school-based therapies, with greater responsibility given to the adolescent, are more 
likely to succeed (Beckman, Hawley, & Bishop, 2006).  Long-term follow-up of behavior 
modification studies have shown some promising results.  In a ten-year follow-up of family-
based behavioral treatment, (n = 42) targeting parent and child for weight loss showed greater 
maintenance of reduced weight compared to targeting the child alone (Epstein, Valoski, Wing, 
& McCurley, 1994).  Perceived cost of implementing a lifestyle change (diet or exercise) can 
be a major impediment to successful, long-term adherence, especially if the change has other 
perceived negative qualities (burdensome, not enjoyable, poor taste, time-consuming, etc), and 
should be addressed by allowing the child some choice in behaviors targeted and reward 
options. 
Behavior modification is based on a rewards system, learning to substitute non-food 
rewards as reinforcement of positive behavior and inducement to continue perceived negative 
changes.  Small and large rewards, and the goal achievement they will correspond to, should be 
determined at the beginning of the program (Stewart, Houghton, Hughes, Pearson, & Reilly, 
2005).  As parental involvement has been shown to improve outcomes for pediatric weight loss, 
it is advantageous to include parents either as weight loss partners if both parent and child are 
overweight, or simply as providing positive reinforcement of goal achievement (Epstein et al., 
1998; Epstein et al., 1994).   12
Diet modification is a major component of the therapy, which includes implementing a 
diet plan simple enough for the child to follow.  The Traffic Light Diet, introduced by Epstein 
and colleagues, is a popular method.  It categorizes foods into Green, Yellow, and Red foods, 
which correspond respectively to foods eaten freely, in moderation, and sparingly, with a 
calorie limit of 900-1200 kcal/d (Epstein et al., 1998).  Interventions utilizing the Traffic Light 
Diet have been effective in decreasing children’s weight while also increasing consumption of 
required nutrients, such as calcium, protein, and vitamins (Epstein et al.).  Other diets advised 
include the diabetic exchange diet, low-glycemic load diet, and the protein-sparing modified 
diet (PSMD).  The diabetic exchange diet categorizes foods into groups based on similar 
nutrient densities.  An individualized meal plan determines the number of exchanges of each 
category (Epstein et al.). The exchange system is easy to follow and exchange information is 
printed on most food labels, further simplifying choices. The low-glycemic load diet uses the 
concept of glycemic index (GI) to guide food choices.  The diet is structured similarly to the 
federal guidelines, with 45%-50% carbohydrate, 15%-25% protein, and 30%-35% fat.  This 
diet has been shown to reduce the postprandial increase in blood glucose and decrease hunger 
throughout the day in single-day studies of overweight children (Kirk et al., 2005).  The 
glycemic load diet has also been shown to result in greater decreases in BMI and % body fat 
than a standard reduced-fat diet (Kirk et al.).  A 2000 study evaluated 107 children randomized 
either to a reduced-fat, energy-restricted diet or a low-GI diet in which children were instructed 
to eat to satiety and snack when hungry.  The low-GI group showed a mean BMI decrease of 
1.15 kg/m
2 compared to no change in the reduced-fat group (Spieth et al., 2000).  The PSMD 
focuses on protein intake, striving for 1.5-2.5g high-quality protein per kilogram body weight.  
This very restrictive diet allows 600-900 kcal/d and is reserved for severely obese, postpubertal   13
children and should be administered under close medical supervision.  The goal of this diet is to 
achieve rapid weight loss while preserving lean muscle mass.  One study showed a weight 
reduction of 11.5 kg over 10 weeks using the PSMD, however at 15 months, weight reduction 
was not different from less restrictive diet plans (Epstein et al.). 
Behavior modification also includes education regarding increasing activity while 
reducing sedentary behaviors (Stewart et al., 2005).  Participants are taught to keep logs of time 
spent in physical activities, including lifestyle activities, and sedentary behaviors.  Epstein and 
colleagues (2004) found that decreasing sedentary behaviors results in weight loss equal to 
targeting an increase in physical activity, due to either a substitution of physical activities 
during time previously spent in sedentary activities or reduced energy intake.  In another study 
by Epstein and colleagues, participants (n = 88) randomized to diet and exercise were markedly 
more successful with weight loss maintenance than the diet alone group at ten-year follow-up.  
Interestingly, the group who participated in lifestyle exercise was even more successful than the 
group that participated in aerobic exercise, as 64% of the lifestyle exercise group (n=42) were < 
20% overweight at 10 year follow-up compared to 58% of the aerobic exercise group (n = 46).  
The weight loss maintenance in both groups was significantly greater than the calisthenics 
control group, but no between-groups analysis was available comparing aerobic to lifestyle 
exercise (Epstein et al., 1994). 
Behavior modification is probably the most accepted form of weight loss intervention 
for the pediatric population.  However, the combination of diet changes, incorporating exercise 
and lifestyle modifications have been found to be difficult to achieve in adult populations and 
could be more difficult with a pediatric population (Barnett et al., 2005).  The tenets of 
behavior modification will, however, lead to a lifetime of improved health, if consistently   14
applied, and therefore are a worthwhile endeavor for the PCP and parents to pursue with the 
child or adolescent. 
 
Prescription Interventions 
Prescription drugs for weight management that have been approved for use in adult 
populations are being prescribed to pediatric patients, although the indications do not include 
children and there is limited testing on the safety and efficacy of these drugs in children.  
However, orlistat and sibutramine have been approved for use in adolescents greater than 16 
years of age (Epstein et al., 1998). 
Sibutramine (Meridia™) is an antiobesity agent designed to inhibit the reuptake of 
norepinephrine and serotonin thereby acting as an appetite suppressant (Berkowitz et al., 2006; 
Epstein et al., 1998).  Sibutramine has been tested in adolescent (>16 years) populations alone 
(n =60) and as an adjuvant to behavioral therapy (n = 498).  In both instances, sibutramine 
significantly increased the mean weight reduction.  As compared to the behavior therapy with 
placebo group, sibutramine plus behavior therapy had greater reduction in BMI (-9.4 kg/m
2 vs -
1.2 kg/m
2) at the end of the 12 month study (Berkowitz et al.; Epstein et al.).  Berkowitz et al 
(2006) also found significant improvements in secondary outcomes such as decreased waist 
circumference, triglyceride levels, and improved HDL, insulin levels, and insulin sensitivity. 
The adverse effects of most concern with sibutramine, as with other norepinephrine 
modulators, are cardiac effects.  In a meta-analysis of adult trials of sibutramine, increases in 
blood pressure were dependent on initial body weight and age, being more pronounced in those 
> 92 kg and < 44 years old.  In a study (n = 361) done by Berkowitz et al (2006), 5 subjects in 
the sibutramine group discontinued therapy due to hypertension compared to none in the   15
placebo group.  Withdrawal due to tachycardia (defined as heart rate >110 beats per minute or 
an increase of >20 bpm) was similar for both groups.  The incidence of other reported adverse 
events was similar for both groups.  Only tachycardia was significantly more frequent in the 
sibutramine group.  However, another study of 52 subjects found no differences in 
cardiovascular measures, comparing sibutramine to placebo in adolescent populations (Godoy-
Matos et al., 2005).  Also, in the study by Godoy-Matos et al., echocardiograms were 
performed on participants (n =52) to investigate a suspected adverse effect of sibutramine on 
cardiac valves, with no adverse effects found.  A study by Zannad and colleagues in adult 
subjects (n = 184) showed no changes in cardiac valves during sibutramine treatment and found 
no increase in blood pressure, but a significant increase in pulse rate in the sibutramine-treated 
group (Zannad et al., 2002).  Gaciong et al (2005) found a significant decreases in blood 
pressure and pulse rate in a 3 month trial of sibutramine (n = 2,225).  It is also demonstrated 
that sibutramine may prolong the QT interval, and case reports suggest this may cause serious 
arrhythmias in some patients, specifically those with long QT syndrome or taking other 
medications known to prolong the QT interval (Harrison-Woolrych, Clark, Hill, Rees, & 
Skinner, 2006).  Overall, sibutramine is acknowledged as a safe and effective drug,  yet it is 
recognized by the FDA as a potential danger to patients, and therefore close monitoring and 
follow-up of any patient taking sibutramine is advised (Wirth & Krause, 2001). 
Orlistat (Xenical™ ) is a gastrointestinal lipase inhibitor, which acts by decreasing 
absorption of fats, thereby promoting their excretion in stool (Krempf et al., 2003).  This 
mechanism of action is meant to act as a catalyst to change eating behaviors, teaching patients 
to reduce and avoid high-fat foods.  In a 2 year study of adults (n = 411), orlistat was shown to 
be effective in weight loss and maintenance over the 2 year period.  Side effects reported by   16
adult patients were minimal, with gastrointestinal events being the most common (Krempf et 
al.).  In 2003, a pilot study with eleven children ages 8 to 12 investigated whether weight 
reduction could be achieved and if children could alter their diets to avoid the adverse effects of 
a high-fat diet (Norgren, Danielsson, Jurold, Lotborn, & Marcus, 2003).  While no formal 
behavioral therapy component was assessed in the pilot study, participants and guardians were 
given information about dietary fat sources and intake guidelines before treatment began.  
Receiving the adult dose of orlistat (120mg at each eating session), participants completed a 12 
week pre-treatment screen and a 12 week treatment program.  Median weight reduction during 
the 12 week treatment program was 4 kg with excellent treatment compliance, in comparison to 
a 2.6 kg weight gain during the 12 week screening session (Norgren et al.).  There is limited 
information reported about adverse effects; it was reported that 2 children prematurely 
withdrew from the study due to excessive diarrhea, suggesting failure to reduce fat 
consumption as recommended.  Vitamin A deficiency was the only biochemical parameter that 
showed significant (p=0.028) decline over the 12 week period, and should be a focus of study 
in longer-term trials (Norgren et al.).  A study (n =539 ) by Chanoine et al (2005) found orlistat 
to be only moderately more effective than placebo over a 2 year period, with both groups 
participating in an exercise and hypocaloric diet program.  The orlistat-treated group, after an 
initial decline in BMI, experienced a stabilization of BMI, while the placebo group had a slight, 
steady increase in BMI through the rest of the study period. 
The social and psychological implications were not found in the literature, especially 
the effect on personal responsibility felt for weight management and rebound weight gain.  This 
would be an interesting area for future research. 
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Over-the-counter supplementation 
Self-medicating is an option many overweight patients attempt as a seemingly easy 
alternative compared to the long, difficult, and often fraught with failure attempts to lose 
weight by conventional methods.  Few randomized, double-blinded studies concerning weight 
loss supplements are in the literature.  However, there are case reports and level II evidence 
(non-biased investigational studies lacking randomization and placebo control) available to 
educate the public. 
Since the ban of ephedra, a sympathomimetic stimulant, in 2004 by the FDA, 
consumers have been looking for a product that delivers similar results.  The new ephedra-free 
supplements contain compounds that have a pharmacokinetic action similar to ephedra, and 
similar adverse effects are being seen.  Bitter orange (Citrus aurantium, the dried peel of bitter 
orange) is Chinese herbal remedy and a popular ephedra substitute.  Available literature 
suggests that bitter orange supplements may cause adverse cardiac events (Haller, Benowitz, & 
Jacob, 2005); case reports of stroke, variant angina, QT prolongation, and possible myocardial 
infarction in which bitter orange containing supplements are suspected of being the causative 
factor were found in the literature (Gange, Madias, Felix-Getzik, Weintraub, & Estes, 2006). 
Guar gum and psyllium, both sources of soluble fiber, are supplements purported to increase 
satiety by absorbing water in the digestive tract.  No good-quality studies support either method 
as a means for weight loss (Saper, Eisenberg, & Phillips, 2004).  Chitosan, derived from chitin 
in crustacean shells, is a positively charged polymer which allegedly prevents fat absorption by 
binding to the negatively charged fat molecules.  Several placebo-controlled studies of chitosan 
have been performed, with contradictory results.  Some have shown no significant difference 
between chitosan groups and placebo (Mhurchu, Dunshea-Mooji, Bennet, & Rodgers, 2005a;   18
Shields, Smock, McQueen, & Bryant, 2003), while others have shown at least a slight 
significant increase in weight loss in the chitosan group (Mhurchu et al., 2005a; Mhurchu, 
Dunshea-Mooji, Bennet, & Rodgers, 2005b).  Chromium, an essential micronutrient, may have 
a role in carbohydrate metabolism and a deficiency of chromium has been linked to 
hyperinsulinemia, hyperglycemia, and hypertriglyceridemia (Saper et al., 2004).  Therefore 
chromium supplementation has been proposed to promote carbohydrate digestion and control 
weight gain, however, randomized controlled trials do not support the link (Egger, Cameron-
Smith, & Stanton, 1999; Saper et al.). 
Based on self-report surveys, 79% of adolescents have used some form of alternative 
medicine in their lifetime, the most popular choices being vitamins, herbal teas.  Most common 
herbal choices are ginseng, zinc, Echinacea, and the above mentioned weight loss supplements. 
(Wilson et al., 2006).  Overall, 46% of adolescents reported using a dietary supplement.  Girls 
are more likely to use supplements than boys (49% v 42%), and use is most prevalent in the 16-
17 year-old cohort (Wilson et al.).  Side effects and drug interactions vary widely with the 
supplements taken, and with the high prevalence of alternative medicine use among youth, a 
careful history is essential to prevent dangerous interactions. 
Recently, the FDA has approved an over-the-counter version of orlistat, called Allì.  
This is the first medication approved for weight loss available over-the-counter (Myers, 2007).  
It has been approved for use in people 18 years or older. Allì will be sold as a 60 mg dose, 
whereas the prescription Xenical is 120mg.  However, studies show that the 60mg dose 
provides 85% of the weight loss benefit seen with the prescriptive dose of 120mg.  The safety 
profile for orlistat in general is fairly good.  Very little of the drug is absorbed systemically, 
limiting its drug-drug interactions and side effects.  Common side effects with Allì are similar   19
to Xenical and include gastrointestinal discomfort and loose stool due to an increase in excreted 
fat (Myers).  It remains to be seen whether the abuse potential will increase with an over-the-
counter version. 
 
Bariatric surgery 
While not a management plan for the primary care office, bariatric surgery is being 
considered increasingly in the adolescent population.  Gastric bypass surgery for morbidly 
overweight adolescents has been practiced since the 1970’s and still randomized, placebo-
controlled studies of efficacy and associated benefits (e.g., comorbidity resolution) are lacking.  
The bariatric inclusion criteria for adolescents are more stringent than those for adults and 
allow for consideration of effects on growth and development (Inge et al., 2004).  Adults must 
have a BMI > 40 or BMI > 35 with severe obesity-related comorbidities to be considered for 
bariatric surgery (Inge et al.).  Adolescents must have a BMI > 40 with severe comorbidities 
(eg type II diabetes, obstructive sleep apnea, metabolic syndrome) or a BMI > 50 with less 
severe comorbidities and at least a 6 month history of failed medically-supervised weight loss 
attempts (Inge et al.).  With a mature patient willing to adhere to the post-surgery lifestyle, 
gastric bypass can be as effective in adolescence as in adult populations, without seriously 
interfering with growth and development (Lawson et al., 2006). 
A comprehensive weight management center (Health Works!, Cincinnati Children’s 
Hospital Medical Center, Cincinnati, OH), which has been performing gastric bypass on 
adolescents since 2001, reports that 1-3 months after surgery, 19% of excess weight was lost, 
33% by 3-6 months, and on average 53% of excess weight was lost at the 2 year point.  A 
retrospective study of 34 bariatric surgery patients, who were adolescents at the time of   20
surgery, report average weight loss of 45-90 kg, with a reduction in BMI from an average of 47 
to an average of 32 (Rand & MacGregor, 1994).  Most patients remain overweight after 
surgery, but the weight loss achieved is sufficient to alleviate many of the co-morbid conditions 
present prior to surgery (Barnett et al., 2005; Rand & MacGregor). 
A meta-analysis of adult bariatric surgery patients shows resolution or improvement of 
many obesity-related conditions, including hypertension, type II diabetes, hyperlipidemia, and 
obstructive sleep apnea (Barnett et al., 2005).  Though information regarding improved health 
among adolescent patients is sparse, the limited information available suggests that these 
benefits extend to the adolescent population as well.  In a retrospective study 6 years after 
surgery, adolescent patients (n =14) report discontinuation of hypertension medication and 
resolution of musculoskeletal pain and obstructive sleep apnea (Barnett et al.). 
Part of the concern in allowing adolescents to undergo bariatric surgery is the radical 
lifestyle changes that must be adhered to after surgery, such as greatly reduced food intake, 
vitamin supplementation, and regular follow-up appointments with medical staff.  Rand and 
McGregor, in their retrospective study, found only 15% of adolescents were compliant with the 
post-operative regimen (Rand & MacGregor, 1994).  However, Lawson et al (2006) state that 
adolescent compliance is no worse than adult compliance with post-operative regimens, which 
suggests that more post-operative support should be offered to any patient undergoing bariatric 
surgery. 
The primary care provider functions as a sort of liaison for bariatric surgery patients.  
The primary care provider should recognize potential candidates for surgery, begin the 
education process, and refer patients to an appropriate surgical site (Presutti, Gorman, & Swain, 
2004).  Primary care providers must be familiar with the various methods of gastric surgery and   21
the potential complications.  As resolution of comorbidities is common after gastric bypass, the 
primary care physician should be aware of changing medication needs.  Also, nutritional 
deficiencies, specifically B12 and iron, should be monitored periodically by the primary care 
provider.  The primary care provider should also be aware of the high percentage of patients, 
especially adolescents, who do not comply with post-surgical regimens, and thus, can provide 
continued education and encouragement (Presutti et al.). 
Bariatric surgery is a major decision for any patient choosing this option.  For the 
pediatric patient, there are the added issues of maturity and ability to comply with necessary 
lifestyle changes, future weight and health issues and appropriateness of surgery for 
adolescents.  By stringently adhering to the criteria set for adolescent bariatric surgery, 
clinicians can offer a chance at weight loss to patients who might otherwise face a lifetime of 
serious morbidity from obesity. 
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Discussion 
It is readily apparent that pediatric overweight is a national crisis, with psychosocial and 
medical consequences that extend far into adulthood.  Given how difficult it has been shown to 
be for adults to fully combat their obesity, it is not surprising that no successful, widely utilized 
management strategy has been found for pediatric patients who, in addition to attempting to 
correct their weight, are facing the normal trials of growing up, may be lacking the cognitive 
tools to fully appreciate their health status, and require even more social & familial support 
than adult obese patients. While even primary care providers fare poorly at detecting 
overweight in their patients, only about half of obese children are diagnosed as obese by their 
provider, the primary care provider may be in the best position to address this issue early for 
the greatest likelihood at achieving a positive outcome (Plourde, 2006).  Pediatric providers 
must be trained in diagnosing and treating pediatric overweight, as lack of specific training has 
been cited as a substantial barrier to initiating treatment (Jelalian et al., 2003).  A supportive 
and persistent primary care provider can help the pediatric patient—educating on healthful diet 
choices, increasing activity & decreasing sedentary behaviors, referring to nutritionist, referring 
for surgery, and involving the entire family for support and role-modeling behaviors, especially 
concerning diet and exercise. 
Parents are key participants in the treatment of pediatric overweight and their support 
and cooperation is needed for any weight loss endeavor.  It has been shown that programs that 
involve the family are more successful than interventions targeting the child alone (Barlow & 
Dietz, 1998; Epstein et al., 1998; Flynn et al., 2006).  Parents have so much control over their 
child’s environment that studies have found that targeting the parent as the agent of change has 
better outcomes than targeting the child (Flynn et al.).  Educating families about the   23
implications and the long-term complications of overweight is the first step in assessing 
readiness of the family to initiate a weight-loss intervention.  If the family is in denial about the 
seriousness of overweight or the possibility of weight loss, any attempt to initiate behavior 
change will most likely fail (Barlow & Dietz).  The Expert Committee on the evaluation and 
treatment of pediatric obesity recommend either delaying the initiation of treatment or referring 
the family to a counselor who can address motivation, misconceptions and denial of the 
condition.  The family must be educated about how to encourage physical activity and 
discourage sedentary behaviors and well as about making healthy food choices.  By having the 
parent in control of the environment, while maintaining the child’s sense of choice, a balance 
can be achieved that results in prolonged behavior changes (Barlow & Dietz; Epstein et al.).  
Ensuring strong family support of pediatric weight loss is the first crucial component necessary 
to implement a successful program, which should be discussed and decided upon by the 
clinician, parents and child (Barlow & Dietz). 
School is another arena in which to focus on pediatric overweight.  Both primary 
(targeting all children) and secondary (targeting children at-risk for overweight) interventions 
have been studied in the school environment.  The consensus of the American Dietetic 
Association is that school based programs should be multifaceted, including physical activity 
and nutrition education (Ritchie et al., 2006).  It is important to avoid a stigmatization of 
children participating in secondary prevention programs.  Initiating secondary prevention 
programs as part of a primary prevention program may be the best way to avoid stigmatization 
and embarrassment (Ritchie et al., 2006). 
Behavioral therapy is the recommended first-line therapy for treating overweight 
pediatric patients, and is the most accepted in terms of treatment administration to growing   24
children.  However, treatment interventions shown to achieve long-term results are very 
intensive programs, requiring specially trained personnel and many hours per patient.  These 
interventions may not be feasible to implement in the primary care setting, depending on the 
level of attention the patient requires.  Referral to obesity clinics might best serve the patient’s 
needs; however, if possible, management in the primary care office, through advice, education 
and other treatment plans deemed necessary might be less stigmatizing for the child and more 
cost-effective for the family, if the clinician is comfortable with treating the level of overweight 
and comorbidities.  Continual reinforcement of the importance of healthy weight attainment 
can increase the likelihood that the patient will undertake a weight loss program and simply 
advising weight loss along with basic education about food choices and exercise can result in 
moderate weight loss in a motivated patient (Saelens et al., 2002). 
Bariatric surgery in the adolescent is limited to a very specific subset of the obese 
adolescent population.  It is, however, the only therapy shown to achieve consistent, long-term 
weight loss (Brolin, 2005).  Complications of therapy can be severe, and it is imperative to 
ensure that both patient and parent fully understand the risks involved.  Adolescent bariatric 
surgery is best performed at a multidisciplinary center, where specialists are available to 
address each component of pre- and post-operative regimens. 
Use of prescription weight-loss medications in adolescents is rapidly becoming a 
legitimate option in the treatment of adolescent overweight.  It remains to be seen if 
mainstream use of antiobesity agents in adolescents will result in apathy and lack of 
responsibility felt for weight loss.  However, for those whom tenacious weight loss efforts have 
failed, sibutramine and orlistat offer another opportunity to achieve their goal.  Interestingly, 
since studies have found that many adolescents’ intake of dietary fat is close to recommended   25
guidelines, it may be that orlistat is ineffectual in that population.  However, it is noted in the 
literature that the majority of preferred snacks in obese population samples are high-fat foods 
(Epstein et al., 1998).  The conflicting results of sibutramine trials regarding the effect on heart 
valves and hemodynamic measures create another obstacle to mainstream use of this drug for 
adolescents.  However, when designing any weight loss plan for a patient, it bears mentioning 
simply to remind practitioners that each patient profile for weight loss will be different, and that 
the approach must be individualized to address the specific patient’s weight issues. 
It is unlikely that obesity in the adult or pediatric population will ever be “cured” by a 
return to ideal body weight (Noller & Paulk, 2005; Whitlock et al., 2005), but without 
persistent clinician intercession, few patients will achieve any sort of improvement and the 
majority will struggle with a lifetime of weight-related disease (Barlow & Dietz, 1998; Moran, 
1999).   26
References 
Barlow, S., & Dietz, W. (1998). Obesity evaluation and treatment: Expert committee 
recommendations. Pediatrics, 102(3). 
Barnett, S. J., Stanley, C., Hanlon, M., Acton, R., Saltzman, D. A., Ikramuddin, S., et al. 
(2005). Long-term follow-up and the role of surgery in adolescents with morbid obesity. 
Surgery for Obesity and Related Diseases, 1, 394-398. 
Beckman, H., Hawley, S., & Bishop, T. (2006). Application of theory-based health behavior 
change techniques to the prevention of obesity in children. Journal of Pediatric 
Nursing, 21(4). 
Berkowitz, R. I., Fujioka, K., Daniels, S., Hoppin, A. G., Owen, S., Perry, A. C., et al. (2006). 
Effects of sibutramine treatment in obese adolescents: A randomized trial. Annals of 
Internal Medicine, 145, 81-90. 
Bialostosky, K., Wright, J. D., Kennedy-Stephenson, J., McDowell, M., & Johnson, C. (2002). 
Dietary intake of macronutrients, micronutrients, and other dietary constituents: United 
States, 1988-1994. 11(245). 
Brolin, R. E. (2005). Postoperative complications in the context of risk:benefit. Surgery for 
Obesity and Related Diseases, 1, 343-347. 
Chanoine, J.-P., Hampl, S., Jensen, C., Boldrin, M., & Hauptman, J. (2005). Effect of orlistat 
on weight and body composition in obese adolescents: A randomized, controlled trial. 
JAMA, 293(23), 2873-2883. 
Dietz, W. (1998). Health consequences of obesity in youth: Childhood predictors of adult 
disease. Pediatrics, 101(3), 518-525.   27
Edmunds, L., Waters, E., & Elliot, E. (2001). Evidence based management of childhood 
obesity. British Medical Journal, 323, 916-919. 
Egger, G., Cameron-Smith, D., & Stanton, R. (1999). The effectiveness of popular, non-
prescription weight loss supplements. Medical Journal of Australia, 171, 604-608. 
Epstein, L. H., Myers, M. D., Raynor, H. A., & Saelens, B. E. (1998). Treatment of pediatric 
obesity. Pediatrics, 101(3), 554-570. 
Epstein, L. H., Paluch, R. A., Kilanowski, C. K., & Raynor, H. A. (2004). The effect of 
reinforcement or stimulus control to reduce sedentary behavior in the treatment of 
pediatric obesity. Health Psychology, 23(4), 371-380. 
Epstein, L. H., Valoski, A., Wing, R. R., & McCurley, J. (1994). Ten-year outcomes of 
behavioral family-based treatment for childhood obesity. Health Psychology, 13(5), 
373-383. 
Flodmark, C. (2005). The happy obese child. International Journal of Obesity, 29, S31-S33. 
Flynn, M. A. T., McNeil, D. A., Maloff, B., Mutasingwa, D., Wu, M., Ford, C., et al. (2006). 
Reducing obesity and related chronic disease risk in children and youth: A synthesis of 
evidence with "best practice" recommendations. Obesity Reviews, 7(1), 7-66. 
Gaciong, Z., & Plancha, G. (2005). Efficacy and safety of sibutramine in 2225 subjects with 
cardiovascular risk factors: Short-term, open-label, observational study. Journal of 
Human Hypertension, 19, 737-743. 
Gange, C. A., Madias, C., Felix-Getzik, E. M., Weintraub, A. R., & Estes, N. A. M. (2006). 
Variant angina associated with bitter orange in a dietary supplement: A case report. 
Mayo Clinic Proceedings, 81(4), 545-548.   28
Gilbert, M. J., & Fleming, M. F. (2006). Pediatricians' approach to obesity prevention 
counseling with their patients. Wisconsin Medical Journal, 105(5), 26-31. 
Godoy-Matos, A., Carraro, L., Vieira, A., Oliveira, J., Guedes, E. P., Mattos, L., et al. (2005). 
Treatment of obese adolescents with sibutramine: A randomized, double-blind, 
controlled study. Journal of Clinical Endocrinology & Metabolism, 90(3), 1460-1465. 
Gortmaker, S. L., Peterson, K., Wiecha, J., Sobol, A. M., Dixit, S., Fox, M. K., et al. (1999). 
Reducing obesity via a school-based interdisciplinary intervention among youth. 
Archives of Pediatric Adolescent Medicine, 153, 409-418. 
Haller, C. A., Benowitz, N. L., & Jacob, P. (2005). Hemodynamic effects of ephedra-free 
weight-loss supplements in humans. American Journal of Medicine, 118, 998-1003. 
Harrison-Woolrych, M., Clark, D. W. J., Hill, G. R., Rees, M. I., & Skinner, J. R. (2006). QT 
interval prolongation associated with sibutramine treatment. British Journal of Clinical 
Pharmacology, 61(4), 464-469. 
Inge, T., Garcia, V., Daniels, S., Langford, L., Kirk, S., Roehrig, H., et al. (2004). A 
multidisciplinary approach to the adolescent bariatric surgery patient. Journal of 
Pediatric Surgery, 39(3), 442-447. 
Jelalian, E., Boergers, J., Alday, C. S., & Frank, R. (2003). Survey of physician attitudes and 
practices related to pediatric obesity. Clinical Pediatrics, 42(3), 235-245. 
Kirk, S., Scott, B., & Daniels, S. (2005). Pediatric obesity epidemic: Treatment options. 
Journal of the American Dietetic Association, 105, S44-51. 
Kitzman, K., & Beech, B. (2006). Family-based interventions for pediatric obesity: 
Methodological and conceptual challenges from family psychology. Journal of Family 
Psychology, 20(2), 175-189.   29
Krempf, M., Louvet, J.-P., Allanic, H., Miloradovich, T., Joubert, J.-M., & Attali, J.-R. (2003). 
Weight reduction and long-term maintenance after 18 months treatment with orlistat for 
obesity. International Journal of Obesity, 27, 591-597. 
Lawson, M., Kirk, S., Mitchell, T., Chen, M., Loux, T. J., Daniels, S., et al. (2006). One-year 
outcomes of Roux-en-Y gastric bypass for morbidly obese adolescents: A multicenter 
study from the Pediatric Bariatric Study Group. Journal of Pediatric Surgery, 41, 137-
143. 
Mhurchu, C. N., Dunshea-Mooji, C., Bennet, D., & Rodgers, A. (2005a). Chitosan for 
overweight or obesity. Cochrane Database of Systematic Reviews, 3. 
Mhurchu, C. N., Dunshea-Mooji, C., Bennet, D., & Rodgers, A. (2005b). Effect of chitosan on 
weight loss in overweight and obese individuals: a systematic review of randomized 
controlled trials. Obesity Reviews, 6, 35-42. 
Mitsnefes, M. M. (2006). Hypertension in children and adolescents. Pediatric Clinics of North 
America, 53(3), 493-512. 
Moran, R. (1999). Evaluation and treatment of childhood obesity. American Family Physician, 
59(4), 861-868. 
Must, A., & Anderson, S. E. (2003). Effects of obesity on morbidity in children and 
adolescents. Nutrition in Clinical Care, 6(1), 4-14. 
Must, A., & Strauss, R. S. (1999). Risks and consequences of childhood and adolescent obesity. 
International Journal of Obesity, 23(2), 2-11. 
Myers, K. A. (2007). Molecule of the month. Current Topics in Medicinal Chemistry, 7(8), 
821.   30
Noller, D. T., & Paulk, D. (2005). Childhood obesity: Curbing an American epidemic. Journal 
of American Academy of Physician Assistant, 18(12), 32-38. 
Norgren, S., Danielsson, P., Jurold, R., Lotborn, M., & Marcus, C. (2003). Orlistat treatment in 
obese prepubertal children: A pilot study. 92, 666-670. 
Ogden, C., Carroll, M., Curtin, L., McDowell, M., Tabak, C., & Flegal, K. (2006). Prevalence 
of overweight and obesity in the United States, 1999-2004. Journal of American 
Medical Association, 295(13), 1549-1555. 
Plourde, G. (2006). Preventing and managing pediatric obesity. Canadian Family Physician, 
52, 322-328. 
Presutti, R. J., Gorman, R. S., & Swain, J. M. (2004). Primary care perspective on bariatric 
surgery. Mayo Clinic Proceedings, 79(9), 1158-1166. 
Rand, C. S. W., & MacGregor, A. M. C. (1994). Adolescents having obesity surgery: A 6-year 
follow-up. Southern Medical Journal, 87(12). 
Ritchie, L., Crawford, P., Hoelscher, D., & Sothern, M. (2006). Position of the American 
Dietetic Association: Individual-, Family-, school-, and community-based interventions 
for pediatric overweight: American Dietetic Association. 
Saelens, B. E., Sallis, J. F., Wilfley, D. E., Patrick, K., Cella, J. A., & Buchta, R. (2002). 
Behavioral weight control for overweight adolescents initiated in primary care. Obesity 
Research, 10(1), 22-32. 
Saper, R. B., Eisenberg, D. M., & Phillips, R. S. (2004). Common dietary supplements for 
weight loss. American Family Physician 70(9), 1731-1738.   31
Shields, K. M., Smock, N., McQueen, C. E., & Bryant, P. J. (2003). Chitosan for weight loss 
and cholesterol management. American Journal of Health-Systems Pharmacology, 60, 
1310-1313. 
Slyper, A. (2004). The pediatric obesity epidemic: Causes and controversies. Journal of 
Clinical Endocrinology & Metabolism, 89(6), 2540-2547. 
Spieth, L. E., Harnish, J., Lenders, C., Raezer, L., Pereira, M., Hangen, J., et al. (2000). A Low-
glycemic index diet in the treatment of pediatric obesity. Archives of Pediatric 
Adolescent Medicine, 154, 947-951. 
Stewart, L., Houghton, J., Hughes, A., Pearson, D., & Reilly, J. (2005). Dietetic management of 
pediatric overweight: Development and description of a practical and evidence-based 
behavioral approach. Journal of the American Dietetic Association, 105(11), 1810-
1814. 
Warschburger, P. (2005). The unhappy obese child. International Journal of Obesity, 29, S127-
129. 
Whitlock, E., Williams, S., Gold, R., Smith, P., & Shipman, S. (2005). Screening and 
intervention for childhood overweight: A summary of evidence for the US Preventive 
Services Task Force. Pediatrics, 116, 125-144. 
Wilson, K. M., Klein, J. D., Sesselberg, T. S., Yussman, S. M., Markow, D. B., Green, A. E., et 
al. (2006). Use of complementary medicine and dietary supplements among U.S. 
adolescents. Journal of Adolescent Health, 38, 385-394. 
Wirth, A., & Krause, J. (2001). Long-term weight loss with sibutramine. JAMA, 286(11), 1331-
1339.   32
Wright, J. D., Wang, C.-Y., Kennedy-Stephenson, J., & Ervin, R. B. (2003). Dietary intake of 
ten key nutrients for public health, United States: 1999-2000: U.S. Department of 
Health and Human Services. 
Young, K. L. (2005). Treating overweight children and adolescents in the clinic. Clinical 
Pediatrics, 44(8), 647-653. 
Zannad, F., Gille, B., Grentzinger, A., Bruntz, J.-F., Hammadi, M., Boivin, J.-M., et al. (2002). 
Effects of sibutramine on ventricular dimensions and heart valves in obese patients 
during weight reduction. American Heart Journal, 144(3).   33
Appendix: Key Points for Clinicians 
o  Address weight issues in a timely manner with parents and child; do not wait until 
health concerns arise to begin education and intervention. 
o  Be direct.  Address weight issues openly and in plain language.   
o  Be familiar with height/weight standards and track both in all pediatric patients. 
o  Inquire about and offer exercise and diet education to all patients, regardless of weight 
status. 
o  Be persistent.  Weight loss will be a long-term commitment and the family will need 
continued support and encouragement. 
o  Have educational reading material available for families, reiterating diet changes and 
exercise suggestions.  
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Abstract 
Objective. This paper examines the current epidemic of pediatric overweight with regard to 
assessment, clinician perspective and treatment options. Pediatric overweight increases the risk 
of obesity in adulthood with increased risk of chronic diseases.  Methods. The literature was 
searched for studies, meta-analyses, and systematic reviews relating to pediatric overweight: 
causes, appropriate assessment, interventions and clinician perception of pediatric overweight. 
Results. Topics with sufficient support in the literature include weight maintenance, behavior 
modification, bariatric surgery, and prescription weight loss drugs, which were reviewed for 
indications for use and efficacy. Over the counter weight loss supplements were included as a 
reference for clinicians.  Conclusion. The intervention of choice for uncomplicated pediatric 
overweight is weight maintenance. Behavior modification is preferred for complicated or 
morbid obesity; however prescription drugs and bariatric surgery are gaining support as 
treatment options for older children with complicated overweight. 
 